How Yervoy Insurance Coverage Affects Out-of-Pocket Costs
Yervoy (ipilimumab), a Bristol Myers Squibb immunotherapy for melanoma and other cancers, has a wholesale acquisition cost around $175,000 for a full treatment course, making insurance pivotal for affordability.[1] Coverage determines copays, coinsurance, deductibles, and prior authorizations, directly shaping patient expenses.
What Coverage Looks Like Under Major Insurers
Medicare Part B covers Yervoy infusions at 80% after the deductible ($240 in 2024), leaving patients with 20% coinsurance—often $20,000-$35,000 per course without caps or assistance.[2] Part D plans vary, with Tier 4 status triggering 25-33% coinsurance post-deductible, though the 2025 Inflation Reduction Act caps out-of-pocket at $2,000 annually for Part D drugs.[3]
Private insurers like UnitedHealthcare or Blue Cross often cover Yervoy after step therapy or genetic testing, with copays from $0-$100 (Tier 3/4) or 20-30% coinsurance. Employer plans cap annual out-of-pocket at $9,450 (individual) under ACA rules.[4] Medicaid covers it fully in most states for approved uses, with minimal copays ($0-$4).
Factors Driving Higher or Lower Out-of-Pocket Expenses
- Deductibles and Phases: High-deductible plans ($1,500-$7,000+) delay full coverage, front-loading costs. Pre-deductible, patients pay 100%.
- Prior Authorization and Denials: 20-30% of claims face delays or denials for off-label use, forcing self-pay until appealed.[5]
- Site of Care: Hospital outpatient infusions cost 40-50% more than physician offices due to facility fees, inflating coinsurance.[6]
- Plan Design: HDHPs with HSAs lower premiums but raise initial OOP; PPOs offer broader networks but higher copays.
Uninsured patients face full list price, though 340B hospitals discount to $10,000-$20,000 per course.
Copay Assistance and Caps That Reduce OOP Burden
Bristol Myers' Access Plus covers copays up to $25,000/year for commercially insured patients (income < $150,000 single).[7] Medicare patients use Independent Foundations like Patient Access Network (up to $14,500/year). Combined, these cut OOP to under $1,000 for eligible patients. State caps (e.g., California limits cancer drug coinsurance to $5,100/year) further help.[8]
Comparing OOP Across Insurance Types
| Insurance Type | Typical OOP per Course (No Assistance) | With Assistance/Caps |
|---------------|---------------------------------------|----------------------|
| Medicare Part B | $20,000-$35,000 (20% coinsurance) | $0-$2,000 |
| Commercial PPO | $5,000-$25,000 (10-30% coinsurance) | $0-$1,000 |
| HDHP | $10,000-$40,000 (full deductible + %) | $0-$5,000 |
| Medicaid | $0-$500 | $0 |
Variability stems from plan specifics; tools like GoodRx or BenefitsCheckUp estimate personalized costs.
Why Coverage Denials Happen and How to Appeal
Denials often cite "experimental use" (10-15% of cases) or preferred alternatives like Opdivo.[9] Appeals succeed 60-70% with medical records; patient advocates or manufacturers assist. Unresolved cases shift to self-pay or compassionate use.
[1] DrugPatentWatch.com
[2] CMS.gov, Medicare Coverage for Immunotherapy
[3] CMS.gov, 2025 Part D Redesign
[4] Healthcare.gov, ACA Out-of-Pocket Maximums
[5] Avalere Health, Oncology Prior Auth Report 2023
[6] USC Schaeffer Center, Site-of-Care Cost Analysis
[7] Bristol Myers Squibb Access Plus Program
[8] California AB 980, Cancer Drug OOP Cap
[9] AJMC, Immunotherapy Denial Rates